Core Insights - Ardelyx, Inc. announced positive results from a post hoc analysis of its IBS-C clinical development program, indicating that Tenapanor (IBSRELA) provides earlier and sustained symptom relief for patients with irritable bowel syndrome with constipation [1][2][4] Group 1: Clinical Findings - The post-hoc analysis pooled data from three clinical trials, showing that patients taking Tenapanor experienced improvements in bowel movement frequency as early as two weeks and significant relief from abdominal symptoms within 4-5 weeks [2] - Continued therapy for 12 weeks increased the likelihood of reporting meaningful symptom improvement across multiple symptoms, emphasizing the importance of sustained treatment [3] Group 2: Practical Implications - The analysis offers week-by-week insights into the timing and durability of Tenapanor's effects, aiding healthcare providers in setting realistic expectations for patients [4] - The sustained response, defined as improvement maintained over consecutive weeks, was observed in some patients, indicating that ongoing therapy is beneficial for achieving symptom relief [4] Group 3: Safety and Tolerability - No new or unexpected safety findings were reported, with Tenapanor generally well tolerated; the most common adverse event was mild-to-moderate diarrhea [4] - In clinical trials, diarrhea occurred in 16% of Tenapanor-treated patients compared to 4% in the placebo group, with severe diarrhea reported in 2.5% of patients [10][9] Group 4: Product Information - IBSRELA (Tenapanor) is a first-in-class retainagogue approved by the FDA for treating IBS-C in adults, acting as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3) [1][6] - The drug works by reducing sodium absorption in the intestines, which helps retain water content and improves stool consistency while also reducing abdominal pain [6] Group 5: Company Overview - Ardelyx is a biopharmaceutical company focused on developing innovative medicines for unmet medical needs, with two commercial products approved in the U.S., including IBSRELA [12] - The company's pipeline includes ongoing Phase 3 development of Tenapanor for chronic idiopathic constipation and a next-generation NHE3 inhibitor [12]

Core Insights - The partnership between the Ladies Professional Golf Association (LPGA) and Ardelyx aims to educate and mobilize patients regarding digestive health, particularly focusing on women suffering from irritable bowel syndrome with constipation (IBS-C) [1][2] Group 1: Partnership Overview - Ardelyx has been named the official corporate pharmaceutical Marketing Partner of the LPGA Tour, marking a first-of-its-kind collaboration [1] - The partnership seeks to empower women to take control of their health and engage in open conversations about digestive health [2] Group 2: Health Focus - Women represent over 90% of individuals living with IBS-C, yet many face stigma and lack awareness, leading to isolation [2] - The collaboration aims to redefine discussions around IBS-C, emphasizing the importance of mental health, relationships, and work productivity affected by the condition [2] Group 3: Engagement Strategies - Ardelyx will implement a 360-degree approach to engage with the LPGA audience, including onsite experiences, storytelling, hospitality, and digital engagement [3] - The partnership will utilize LPGA platforms to distribute original digital and social content aimed at educating and connecting patients [2][3] Group 4: Organizational Background - The LPGA, established in 1950, is the premier women's professional golf organization, representing nearly 40 countries and providing opportunities for female golfers [4] - Ardelyx focuses on developing innovative medicines to address significant unmet medical needs, with two commercial products approved in the U.S. [6][7]

Core Insights - Ardelyx, Inc. presented data on XPHOZAH at the American Society of Nephrology's Kidney Week, highlighting its effectiveness in real-world settings for patients with chronic kidney disease on dialysis [1][3] Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the United States: IBSRELA and XPHOZAH, with ongoing development of next-generation therapies [15][16] Product Information - XPHOZAH is the first phosphate absorption inhibitor approved by the FDA for reducing serum phosphorus in adults with chronic kidney disease on dialysis [2][14] - It is administered as a single tablet taken twice daily and works by blocking phosphate absorption in the gut [2][10] Clinical Study Results - The first real-world study of XPHOZAH showed that patients experienced an average reduction in serum phosphate of nearly 1 mg/dL, with 45.3% of participants achieving a reduction of ≥1 mg/dL [3][4] - A separate survey indicated that 63% of patients reported improved phosphate levels since starting tenapanor, with 69% feeling better about their phosphate control [4] Patient Experience - Positive patient experiences were reported, including improved bowel movements and lower pill burden, with 44% attributing improvements to better phosphate control [4] - Tenapanor also demonstrated effectiveness in improving bowel movements in patients with end-stage kidney disease and constipation [6][7] Economic Analysis - A cost-effectiveness analysis in Japan concluded that tenapanor is cost-effective for hemodialysis patients, meeting the threshold of five million Japanese Yen for willingness to pay [8]

Core Points - Ardelyx, Inc. will hold a conference call on October 30, 2025, at 4:30 p.m. Eastern Time to discuss third-quarter financial results and provide a business update [1] - The conference call will be accessible via phone and will also be webcasted live on the company's website, with a replay available for 30 days [2] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3]

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Mike Raab, President and CEO of Ardelyx, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on June 4, 2025, at 8:10 am ET in New York [1] - A live webcast of the panel presentation will be accessible on the Ardelyx website, with a replay available for 30 days post-event [2]

Core Insights - Ardelyx, Inc. presented data on IBSRELA (tenapanor) and findings from the IBS in America 2024 Real-World Survey at the Digestive Disease Week Conference, highlighting the correlation between IBS-C symptom severity and financial hardship [1][2] Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines to address significant unmet medical needs, with two commercial products approved in the U.S.: IBSRELA and XPHOZAH [13] Product Information - IBSRELA (tenapanor) is approved by the FDA for treating irritable bowel syndrome with constipation (IBS-C) in adults, acting as a sodium/hydrogen exchanger 3 (NHE3) inhibitor to improve intestinal transit and stool consistency [1][6][12] - The drug has shown efficacy in reducing abdominal pain and improving gastrointestinal symptoms in clinical studies [6] Survey Findings - The IBS in America 2024 Real-World Survey revealed that higher severity of IBS-C symptoms is linked to increased financial burden, assessed using the Functional Assessment of Chronic Illness Therapy Measure of Financial Toxicity (FACIT-COST®) [2] - The survey utilized Patient-Reported Outcomes Measurement Information System® (PROMIS®) gastrointestinal symptom scales to evaluate the impact of IBS on patients' quality of life [2] Safety and Tolerability - Interim results from a Phase 3 study indicated that tenapanor was well-tolerated in pediatric patients aged 12 to 18, with diarrhea being the only adverse event related to the drug [3] - A separate pharmacokinetic study found that tenapanor and its major metabolite were not detectable in the breast milk of lactating females after four days of dosing, indicating a favorable safety profile [4] Market Context - IBS-C affects an estimated 12 million people in the U.S., leading to significant economic burden and impaired quality of life, highlighting the need for effective treatments like IBSRELA [7]

Core Insights - Ardelyx, Inc. is set to present data on its first-in-class retainagogue, IBSRELA (tenapanor), at the Digestive Disease Week Conference, highlighting its approval for treating irritable bowel syndrome with constipation (IBS-C) in adults [1] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative medicines that address significant unmet medical needs [11] - The company has two commercial products approved in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [11] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [11] Product Information - IBSRELA (tenapanor) acts as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which helps retain luminal water content, accelerating intestinal transit time and resulting in softer stool consistency [4] - The drug has been shown to reduce abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models [4] - IBSRELA is indicated for the treatment of IBS-C in adults, with a significant patient population of approximately 12 million affected in the U.S. [5][10] Clinical Data Presentation - Ardelyx will sponsor a Product Theater at the conference, focusing on integrating a different mechanism of action into the treatment of IBS-C, featuring clinical considerations and data from two Phase 3 clinical trials [3]

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the United States: IBSRELA and XPHOZAH, both containing the active ingredient tenapanor [12] Product Information - XPHOZAH (tenapanor) is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. FDA for reducing serum phosphorus in adults with chronic kidney disease (CKD) on dialysis [2][11] - It is indicated as add-on therapy for patients who have an inadequate response to phosphate binders or are intolerant to any dose of phosphate binder therapy [11] - XPHOZAH operates through a unique mechanism that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily [2][6] Clinical Study Insights - The OPTIMIZE Study was a randomized, open-label trial involving 330 patients with CKD on dialysis and hyperphosphatemia, aimed at evaluating methods for initiating XPHOZAH to optimize phosphorus management [3] - A post-hoc analysis of this study has been accepted for presentation at the National Kidney Foundation Spring Clinical Meetings [1][4] Safety and Efficacy - Diarrhea was the most common side effect reported in clinical trials, occurring in 43-53% of patients, with severe diarrhea reported in 5% of patients [10] - The majority of diarrhea events were mild-to-moderate and typically resolved over time or with dose reduction [10] Industry Context - Hyperphosphatemia is a serious condition affecting the majority of the 550,000 patients in the U.S. with CKD on maintenance dialysis, necessitating effective management strategies [7] - The KDIGO treatment guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5-4.5 mg/dL [7]